No profile data available.
Rapt Therapeutics, Inc. (RAPT) is a healthcare company in the allergy treatment pharmaceuticals industry, based in South San Francisco, United States, with about 60 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$129.87 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $1.68 billion.
Figures from company filings and market data; latest fiscal year ended December 31, 2024.
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
Rapt Therapeutics reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$1.68 billion.
Listed companies of a similar size in the same industry (allergy treatment pharmaceuticals) include ALK-Abelló A/S (ALK-B.CO), Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (300357.SZ), DBV Technologies S.a. (DBVT), ARS Pharmaceuticals, Inc. (SPRY).